Posted 3/27/2024, 11:00:00 AM
iBio and AstralBio Team Up to Tackle Obesity Through AI and Biologics
- iBio and AstralBio announcing collaboration to use AI and biologics to develop novel obesity treatments
- iBio granting AstralBio exclusive license to 4 cardiometabolic disease targets; iBio gets rights to 3 AstralBio targets
- Companies initiating development of lead program targeting TGFb superfamily for muscle wasting and obesity
- iBio confident its AI technology can develop antibodies against challenging cardiometabolic targets
- Collaboration aims to rapidly build best-in-class cardiometabolic disease portfolio by combining companies' strengths